177 related articles for article (PubMed ID: 31741138)
1. Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system.
Nakajima Y; Nogami K; Yada K; Kawamura T; Ogiwara K; Furukawa S; Shimonishi N; Takeyama M; Shima M
Int J Hematol; 2020 Mar; 111(3):369-377. PubMed ID: 31741138
[TBL] [Abstract][Full Text] [Related]
2. Assessing the clinical severity of type 1 von Willebrand disease patients with a microchip flow-chamber system.
Nogami K; Ogiwara K; Yada K; Shida Y; Takeyama M; Yaoi H; Minami H; Furukawa S; Hosokawa K; Shima M
J Thromb Haemost; 2016 Apr; 14(4):667-74. PubMed ID: 27061057
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchip-based flow chamber system.
Ogiwara K; Nogami K; Hosokawa K; Ohnishi T; Matsumoto T; Shima M
Haemophilia; 2015 Jan; 21(1):71-80. PubMed ID: 25545301
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system.
Ågren A; Holmström M; Schmidt DE; Hosokawa K; Blombäck M; Hjemdahl P
Thromb Haemost; 2017 Jan; 117(1):75-85. PubMed ID: 27761577
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of the Total Thrombus-Formation Analysis System (T-TAS) in the diagnosis and characterization of von Willebrand disease.
Daidone V; Barbon G; Cattini MG; Pontara E; Romualdi C; Di Pasquale I; Hosokawa K; Casonato A
Haemophilia; 2016 Nov; 22(6):949-956. PubMed ID: 27293213
[TBL] [Abstract][Full Text] [Related]
6. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
Swystun LL; Georgescu I; Mewburn J; Deforest M; Nesbitt K; Hebert K; Dwyer C; Brown C; Notley C; Lillicrap D
J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
[TBL] [Abstract][Full Text] [Related]
7. A microchip flow-chamber assay screens congenital primary hemostasis disorders.
Nakajima Y; Yada K; Ogiwara K; Furukawa S; Shimonishi N; Shima M; Nogami K
Pediatr Int; 2021 Feb; 63(2):160-167. PubMed ID: 32640065
[TBL] [Abstract][Full Text] [Related]
8. Clinical phenotype in genetically confirmed von Willebrand disease type 2N patients reflects a haemophilia A phenotype.
van Meegeren ME; Mancini TL; Schoormans SC; van Haren BJ; van Duren C; Diekstra A; Laros-van Gorkom BA; Brons PP; Simons A; Hoefsloot L; van Heerde WL
Haemophilia; 2015 Sep; 21(5):e375-83. PubMed ID: 26207643
[TBL] [Abstract][Full Text] [Related]
9. Laboratory Testing for von Willebrand Factor: Factor VIII Binding for the Diagnosis or Exclusion of Type 2N von Willebrand Disease: An Update.
Favaloro EJ; Mohammed S; Vong R; Pasalic L
Methods Mol Biol; 2023; 2663():679-691. PubMed ID: 37204745
[TBL] [Abstract][Full Text] [Related]
10. Type 2N von Willebrand disease: Characterization and diagnostic difficulties.
Casonato A; Galletta E; Sarolo L; Daidone V
Haemophilia; 2018 Jan; 24(1):134-140. PubMed ID: 29115006
[TBL] [Abstract][Full Text] [Related]
11. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions.
Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
Thromb Res; 2021 Feb; 198():7-16. PubMed ID: 33248318
[TBL] [Abstract][Full Text] [Related]
12. Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees.
Qin HH; Xing ZF; Wang XF; Ding QL; Xi XD; Wang HL
Blood Cells Mol Dis; 2014 Apr; 52(4):181-5. PubMed ID: 24351655
[TBL] [Abstract][Full Text] [Related]
13. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
Veyradier A; Caron C; Ternisien C; Wolf M; Trossaert M; Fressinaud E; Goudemand J
Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
[TBL] [Abstract][Full Text] [Related]
14. Detection of acquired von Willebrand syndrome after ventricular assist device by total thrombus-formation analysis system.
Takashio S; Kaikita K; Nishi M; Morioka M; Higo T; Shiose A; Doman T; Horiuchi H; Fukui T; Tsujita K
ESC Heart Fail; 2020 Oct; 7(5):3235-3239. PubMed ID: 32700467
[TBL] [Abstract][Full Text] [Related]
15. Von Willebrand disease type 2N: An update.
Seidizadeh O; Peyvandi F; Mannucci PM
J Thromb Haemost; 2021 Apr; 19(4):909-916. PubMed ID: 33497541
[TBL] [Abstract][Full Text] [Related]
16. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
17. Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition.
Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
Haemophilia; 2021 Mar; 27(2):e194-e203. PubMed ID: 33555083
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
Miller CH; Kelley L; Green D
Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive re-evaluation of historical von Willebrand disease diagnosis in association with whole blood platelet aggregation and function.
Nummi V; Lassila R; Joutsi-Korhonen L; Armstrong E; Szanto T
Int J Lab Hematol; 2018 Jun; 40(3):304-311. PubMed ID: 29427305
[TBL] [Abstract][Full Text] [Related]
20. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
